Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook

Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr

Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US

Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint

The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)

Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl

Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use

Vimta Labs Q1 FY26 PAT climbs to Rs. 18.89 Cr

Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru

This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms

Plant-based chemistry essential for home and personal care products: Vishal Sharma, Executive Director & Chief Executive Officer (Chemicals), Godrej Industries

Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,